Joyo

This research aims to evaluate the long-term safety and explore the efficacy of astegolimab in adults aged 40 to 90 years with chronic obstructive pulmonary disease COPD. It focuses on participants who have completed a 52-week placebo-controlled treatment period in previous studies GB43311 or GB44332. The study is a phase 3, open-label extension to gather extended safety information on this drug in COPD patients. Participants from the parent studies who qualify will receive subcutaneous injections of astegolimab every two weeks throughout the study until it ends. This open-label extension allows all participants to receive the active drug without placebo comparison. The study continues treatment beyond the initial 52-week period to monitor long-term effects. During the study, participants will be monitored for adverse events up to 12 weeks after their last dose of astegolimab. Researchers will collect safety data to understand the incidence of any side effects. The study involves regular assessments and follow-ups to ensure participant well-being, with the total duration lasting until July 2034.

This research aims to clarify how sleep hygiene relates to the development of sarcopenia muscle loss and cognitive dysfunction in patients with chronic obstructive pulmonary disease COPD or idiopathic pulmonary fibrosis IPF. It focuses on measuring sleep time, arousal, and sleep quality to understand their effects on disease progression and life expectancy in these patients. Sleep-related disorders like insomnia and sleep apnea are common in COPD and IPF and may contribute to daytime sleepiness, reduced daily activities, depression, and cognitive issues. The study observes patients with COPD or IPF without providing any specific treatment or intervention. Researchers will monitor participants sleep patterns, including sleep time and sleep efficiency, as well as arousal during sleep. These indicators will be used to explore their relationship with the onset of sarcopenia and mild cognitive impairment over a two-year period. The study also examines how these sleep factors relate to hospitalizations and mortality from disease exacerbations. Participants will undergo assessments at enrollment and during follow-up to measure sleep quality, muscle strength, walking speed, skeletal muscle mass, and cognitive function. Researchers will track changes in these areas and record hospitalizations and deaths related to COPD or IPF exacerbations over two years. The main outcome is the link between sleep time at enrollment and the development of sarcopenia during follow-up, with secondary outcomes including cognitive impairment and other health changes. The study includes close monitoring but does not involve experimental treatments.

Researchers are studying bronchiectasis in adults and adolescents aged 12 to under 18 who produce sputum and have experienced flare-ups. The trial aims to evaluate whether the medicine BI 1291583 can help reduce these flare-ups compared to a placebo. Participants are randomly assigned to receive either BI 1291583 or a placebo in a phase III, double-blind study. Participants take one tablet of either BI 1291583 or placebo once daily for up to 1 year and 6 months. The study includes two groups one receiving the active medication and the other receiving placebo tablets that look identical but contain no medicine. The study period lasts up to 1 year and 8 months, during which participants attend up to 10 site visits and receive about 13 phone calls. During the study, participants regularly record their bronchiectasis symptoms in a smartphone diary. Study doctors monitor participants health, note any flare-ups, and check for unwanted effects. Researchers compare the number of flare-ups between the two groups as the primary measure. Secondary measures include time to first flare-up, quality of life changes, lung function changes, and rates of severe flare-ups.